Multiple System Atrophy Clinical Trial
— SCAtACSOfficial title:
Interventional Cross-over Study to Evaluate the Efficacy on Motor and Cognitive Performance of Transcranial Alternating Current Stimulation (tACS) in Patients With Neurodegenerative Ataxia
Verified date | December 2022 |
Source | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of the study is to evaluate the effects on motor and cognitive performance of transcranial alternating current stimulation (tACS) compared to transcranial direct current stimulation (tDCS) and placebo stimulation (sham) in patients with neurodegenerative ataxia to identify a possible rehabilitation protocol.
Status | Completed |
Enrollment | 26 |
Est. completion date | December 10, 2022 |
Est. primary completion date | December 10, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with a cerebellar syndrome and quantifiable cerebellar atrophy Exclusion Criteria: - Severe head trauma in the past - History of seizures - History of ischemic stroke or hemorrhage - Pacemaker - Metal implants in the head/neck region - Severe comorbidity - Intake of illegal drugs - Pregnancy |
Country | Name | City | State |
---|---|---|---|
Italy | ASST Spedali Civili di Brescia | Brescia | BS |
Lead Sponsor | Collaborator |
---|---|
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia |
Italy,
Benussi A, Cantoni V, Manes M, Libri I, Dell'Era V, Datta A, Thomas C, Ferrari C, Di Fonzo A, Fancellu R, Grassi M, Brusco A, Alberici A, Borroni B. Motor and cognitive outcomes of cerebello-spinal stimulation in neurodegenerative ataxia. Brain. 2021 Sep 4;144(8):2310-2321. doi: 10.1093/brain/awab157. — View Citation
Benussi A, Dell'Era V, Cantoni V, Bonetta E, Grasso R, Manenti R, Cotelli M, Padovani A, Borroni B. Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial. Neurology. 2018 Sep 18;91(12):e1090-e1101. doi: 10.1212/WNL.0000000000006210. Epub 2018 Aug 22. — View Citation
Benussi A, Dell'Era V, Cotelli MS, Turla M, Casali C, Padovani A, Borroni B. Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia. Brain Stimul. 2017 Mar-Apr;10(2):242-250. doi: 10.1016/j.brs.2016.11.001. Epub 2016 Nov 3. — View Citation
Benussi A, Koch G, Cotelli M, Padovani A, Borroni B. Cerebellar transcranial direct current stimulation in patients with ataxia: A double-blind, randomized, sham-controlled study. Mov Disord. 2015 Oct;30(12):1701-5. doi: 10.1002/mds.26356. Epub 2015 Aug 14. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the International Cooperative Ataxia Rating Scale (ICARS) Score From Baseline | International Cooperative Ataxia Rating Scale (ICARS): semi-quantitative 100-point scale, yielding a total score of 0 (no ataxia) to 100 (most severe ataxia). | Baseline (immediately before the intervention) - Immediately after the intervention | |
Primary | Change in the Scale for the Assessment and Rating of Ataxia (SARA) Score From Baseline | Scale for the Assessment and Rating of Ataxia (SARA): 8-item performance based scale, yielding a total score of 0 (no ataxia) to 40 (most severe ataxia). | Baseline (immediately before the intervention) - Immediately after the intervention | |
Secondary | Change in Cerebellar Brain Inhibition (CBI) Measurements From Baseline | Cerebellar brain inhibition (CBI) is expressed as motor evoked potential amplitude (average of 10 recordings). Lower values reflect higher inhibition and thus reduced impairment. | Baseline (immediately before the intervention) - Immediately after the intervention | |
Secondary | Change in Timed Up and Go Test Duration From Baseline | Time (in seconds) that a person takes to rise from a chair, walk three meters, turn around 180 degrees, walk back to the chair, and sit down while turning 180 degrees, assessed with gait sensors. | Baseline (immediately before the intervention) - Immediately after the intervention | |
Secondary | Change in Walking Cadence From Baseline | Average Left and Right Steps/Minute during a 60 seconds walk, assessed with gait sensors. | Baseline (immediately before the intervention) - Immediately after the intervention | |
Secondary | Change in 360° Turn From Baseline | Velocity (Number of Degrees/sec) in making a 360° turn, assessed with gait sensors | Baseline (immediately before the intervention) - Immediately after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03593512 -
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
|
N/A | |
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Recruiting |
NCT02897063 -
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
|
Phase 1 | |
Not yet recruiting |
NCT00758849 -
Fipamezole in Neurogenic Orthostatic Hypotension
|
Phase 2 | |
Completed |
NCT01155492 -
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04431713 -
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
|
Phase 2 | |
Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
Recruiting |
NCT05121012 -
Synaptic Loss in Multiple System Atrophy
|
||
Terminated |
NCT03589976 -
A Futility Trial of Sirolimus in Multiple System Atrophy
|
Phase 2 | |
Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
Recruiting |
NCT04876326 -
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
|
N/A | |
Recruiting |
NCT04680065 -
GDNF Gene Therapy for Multiple System Atrophy
|
Phase 1 | |
Completed |
NCT03753763 -
Safinamide for Multiple System Atrophy (MSA)
|
Phase 2 | |
Recruiting |
NCT04250493 -
Insulin Resistance in Multiple System Atrophy
|
N/A | |
Recruiting |
NCT06072105 -
Medical Decision Making in Multiple System Atrophy
|
N/A | |
Terminated |
NCT02149901 -
Water and Sudafed in Autonomic Failure
|
Early Phase 1 | |
Terminated |
NCT00997672 -
Lithium in Multiple System Atrophy
|
Phase 2 |